Video

Common Pitfalls With Treating Soft Tissue Sarcoma

Related Videos
Alec Watson, MD
Sagar D. Sardesai, MBBS
Brian A. Van Tine, MD, PhD
DB-12
Balazs Halmos, MD
Balazs Halmos, MD
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Related Content
Ovarian Cancer
December 20th 2024

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com
December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Image Credit: © Anatomy Insider - stock.adobe.com
December 19th 2024

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab